MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma

Journal of Biological Chemistry

Volumn 288, Issue 29, 2013, Pages 21307-21319

  Van Der Deen, Margaretha ^a   Taipaleenmäki, Hanna ^a,b   Zhang, Ying ^a   Teplyuk, Nadiya M ^a   Gupta, Anurag ^a   Cinghu, Senthilkumar ^a   Shogren, Kristen ^c   Maran, Avudaiappan ^c   Yaszemski, Michael J ^c   Ling, Ling ^d   Cool, Simon M ^d,e   Leong, David T ^f   Dierkes, Christian ^g   Zustin, Jozef ^b   Salto Tellez, Manuel ^h,i   Ito, Yoshiaki ⁱ   Bae, Suk Chul ^j   Zielenska, Maria ^k   Squire, Jeremy A ^l   Lian, Jane B ^a,m   Stein, Janet L ^a,m   Zambetti, Gerard P ⁿ   Jones, Stephen N ^a   Galindo, Mario ^o   Hesse, Eric ^b   Stein, Gary S ^a,m   Van Wijnen, Andre J ^a,c,d,e   more..

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c MAYO CLINIC   (United States)

^d INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g Research Park Trier   (Germany)

^h QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^j Chungbuk National University   (South Korea)

^k HOSPITAL FOR SICK CHILDREN   (Canada)

^l QUEEN S UNIVERSITY   (Canada)

^m UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

ⁿ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^o UNIVERSITY OF CHILE   (Chile)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FUNCTIONS; OSTEOSARCOMA; TUMOR SUPPRESSORS;

BIOCHEMISTRY; BIOLOGY;

TUMORS;

MICRORNA; MICRORNA 34C; PROTEIN P53; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MESENCHYMAL STEM CELL; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; TRANSCRIPTION REGULATION; TUMOR BIOPSY; UBIQUITINATION;

MICRORNA; OSTEOSARCOMA; P53; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR GENE;

ANIMALS; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DOWN-REGULATION; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICRORNAS; OSTEOSARCOMA; PROTEIN STABILITY; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880567685     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.445890     Document Type: Article

References (46)

1. Kansara, M., and Thomas, D. M. (2007) Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 26,1-18
2. Jensen, E. D., Gopalakrishnan, R., and Westendorf, J. J. (2010) Regulation of gene expression in osteoblasts. Biofactors 36, 25-32
3. Marie, P. J. (2008) Transcription factors controlling osteoblastogenesis. Arch. Biochem. Biophys. 473, 98 -105
4. Martin, J. W., Zielenska, M., Stein, G. S., van Wijnen, A. J., and Squire, J. A. (2011) The role of RUNX2 in osteosarcoma oncogenesis. Sarcoma 2011, 282745
5. Fuchs, B., and Pritchard, D. J. (2002) Etiology of osteosarcoma. Clin. Orthop. Relat. Res. 397, 40-52
6. Hansen, M. F. (1991) Molecular genetic considerations in osteosarcoma. Clin. Orthop. Relat. Res. 270, 237-246
7. Berman, S. D., Calo, E., Landman, A. S., Danielian, P. S., Miller, E. S., West, J. C., Fonhoue, B. D., Caron, A., Bronson, R., Bouxsein, M. L., Mukherjee, S., and Lees, J. A. (2008) Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc. Natl. Acad. Sci. U.S.A. 105, 11851-11856
8. Walkley, C. R., Qudsi, R., Sankaran, V. G., Perry, J. A., Gostissa, M., Roth, S. I., Rodda, S. J., Snay, E., Dunning, P., Fahey, F. H., Alt, F. W., McMahon, A. P., and Orkin, S. H. (2008) Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 22, 1662-1676
9. Lengner, C. J., Steinman, H. A., Gagnon, J., Smith, T. W., Henderson, J. E., Kream, B. E., Stein, G. S., Lian, J. B., and Jones, S. N. (2006) Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J. Cell Biol. 172, 909-921
10. Lian, J. B., Stein, G. S., Javed, A., van Wijnen, A. J., Stein, J. L., Montecino, M., Hassan, M. Q., Gaur, T., Lengner, C. J., and Young, D. W. (2006) Networks and hubs for the transcriptional control of osteoblastogenesis. Rev. Endocr. Metab. Disord. 7,1-16
11. Galindo, M., Pratap, J., Young, D. W., Hovhannisyan, H., Im, H. J., Choi, J. Y., Lian, J. B., Stein, J. L., Stein, G. S., and van Wijnen, A. J. (2005) The bone-specific expression of RUNX2 oscillates during the cell cycle to support a G1-related anti-proliferative function in osteoblasts. J. Biol. Chem. 280, 20274-20285
12. Nathan, S. S., Pereira, B. P., Zhou, Y. F., Gupta, A., Dombrowski, C., Soong, R., Pho, R. W., Stein, G. S., Salto-Tellez, M., Cool, S. M., and van Wijnen, A. J. (2009) Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol. Biol. Rep. 36,153-158
13. Pratap, J., Galindo, M., Zaidi, S. K., Vradii, D., Bhat, B. M., Robinson, J. A., Choi, J.-Y., Komori, T., Stein, J. L., Lian, J. B., Stein, G. S., and van Wijnen, A. J. (2003) Cell growth regulatory role of Runx2 during proliferative expansion of pre-osteoblasts. Cancer Res. 63, 5357-5362
14. Teplyuk, N. M., Galindo, M., Teplyuk, V. I., Pratap, J., Young, D. W., Lapointe, D., Javed, A., Stein, J. L., Lian, J. B., Stein, G. S., and van Wijnen, A. J. (2008) Runx2 regulates G-protein coupled signaling pathways to control growth of osteoblast progenitors. J. Biol. Chem. 283,27585-27597
15. Martin, J. W., Yoshimoto, M., Ludkovski, O., Thorner, P. S., Zielenska, M., Squire, J. A., and Nuin, P. A. (2010) Analysis of segmental duplications, mouse genome synteny, and recurrent cancer-associated amplicons in human chromosome 6p21-p12. Cytogenet. Genome Res. 128,199-213
16. Pereira, B. P., Zhou, Y., Gupta, A., Leong, D. T., Aung, K. Z., Ling, L., Pho, R. W., Galindo, M., Salto-Tellez, M., Stein, G. S., Cool, S. M., van Wijnen, A. J., and Nathan, S. S. (2009) Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1). J. Cell Physiol. 221, 778-788
17. San Martin, I. A., Varela, N., Gaete, M., Villegas, K., Osorio, M., Tapia, J. C., Antonelli, M., Mancilla, E. E., Pereira, B. P., Nathan, S. S., Lian, J. B., Stein, J. L., Stein, G. S., van Wijnen, A. J., and Galindo, M. (2009) Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbf in osteosarcoma cells. J. Cell Physiol. 221, 560-571
18. Pratap, J., Lian, J. B., and Stein, G. S. (2011) Metastatic bone disease. Role of transcription factors and future targets. Bone 48, 30-36
19. Wang, X., Kua, H. Y., Hu, Y., Guo, K., Zeng, Q., Wu, Q., Ng, H. H., Karsenty, G., de Crombrugghe, B., Yeh, J., and Li, B. (2006) p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent oste-oclastogenesis, and bone remodeling. J. Cell Biol. 172, 115-125
20. Westendorf, J. J., Zaidi, S. K., Cascino, J. E., Kahler, R., van Wijnen, A. J., Lian, J. B., Yoshida, M., Stein, G. S., and Li, X. (2002) Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/ WAF1) promoter. Mol. Cell. Biol. 22, 7982-7992
21. Das, K., Leong, D. T., Gupta, A., Shen, L., Putti, T., Stein, G. S., van Wijnen, A. J., and Salto-Tellez, M. (2009) Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur. J. Cancer 45, 2239-2248
22. Das, K., Mohd Omar, M. F., Ong, C. W., Bin Abdul Rashid, S., Peh, B. K., Putti, T. C., Tan, P. H., Chia, K. S., Teh, M., Shah, N., Soong, R., and Salto-Tellez, M. (2008) TRARESA. A tissue microarray-based hospital system for biomarker validation and discovery. Pathology 40, 441- 449
23. Ong, C. W., Kim, L. G., Kong, H. H., Low, L. Y., Wang, T. T., Supriya, S., Kathiresan, M., Soong, R., and Salto-Tellez, M. (2010) Computer-assisted pathological immunohistochemistry scoring is more time-effective than conventional scoring, but provides no analytical advantage. Histopathol-ogy 56, 523-529
24. Chi, X. Z., Kim, J., Lee, Y. H., Lee, J. W., Lee, K. S., Wee, H., Kim, W. J., Park, W. Y., Oh, B. C., Stein, G. S., Ito, Y., van Wijnen, A. J., Bae, S. C. (2009) Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination. Cancer Res. 69, 8111-8119
25. Choi, J.-Y., Pratap, J., Javed, A., Zaidi, S. K., Xing, L., Balint, E., Dalamangas, S., Boyce, B., van Wijnen, A. J., Lian, J. B., Stein, J. L., Jones, S. N., and Stein, G. S. (2001) Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development. Proc. Natl. Acad. Sci. U.S.A. 98, 8650- 8655
26. Zaidi, S. K., Sullivan, A. J., Medina, R., Ito, Y., van Wijnen, A. J., Stein, J. L., Lian, J. B., and Stein, G. S. (2004) Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J. 23, 790-799
27. Zhang, Y., Hassan, M. Q., Xie, R. L., Hawse, J. R., Spelsberg, T. C., Monte-cino, M., Stein, J. L., Lian, J. B., van Wijnen, A. J., and Stein, G. S. (2009) Co-stimulation of the bone-related Runx2 P1 promoter in mesenchymal cells by SP1 and ETS transcription factors at polymorphic purine-rich DNA sequences (Y-repeats). J. Biol. Chem. 284, 3125-3135
28. Young, D. W., Hassan, M. Q., Pratap, J., Galindo, M., Zaidi, S. K., Lee, S. H., Yang, X., Xie, R., Javed, A., Underwood, J. M., Furcinitti, P., Imbalzano, A. N., Penman, S., Nickerson, J. A., Montecino, M. A., Lian, J. B., Stein, J. L., van Wijnen, A. J., and Stein, G. S. (2007) Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 445, 442-446
29. Thomas, D. M., Johnson, S. A., Sims, N. A., Trivett, M. K., Slavin, J. L., Rubin, B. P., Waring, P., McArthur, G. A., Walkley, C. R., Holloway, A. J., Diyagama, D., Grim, J. E., Clurman, B. E., Bowtell, D. D., Lee, J. S., Gutierrez, G. M., Piscopo, D. M., Carty, S. A., and Hinds, P. W. (2004) Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J. Cell Biol. 167, 925-934
30. Sadikovic, B., Thorner, P., Chilton-Macneill, S., Martin, J. W., Cervigne, N. K., Squire, J., and Zielenska, M. (2010) Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer 10, 202
31. Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K. H., and Peters, G. (1998) The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001-5014
32. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., and Liu, E. A. (2004) In vivo activation ofthe p53 pathwaybysmall-molecule antagonists of MDM2. Science 303, 844- 848
33. Jones, K. B., Salah, Z., Del Mare, S., Galasso, M., Gaudio, E., Nuovo, G. J., Lovat, F., LeBlanc, K., Palatini, J., Randall, R. L., Volinia, S., Stein, G. S., Croce, C. M., Lian, J. B., Aqeilan, R. I. (2012) miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 72, 1865-1877
34. Zhang, Y., Xie, R. L., Croce, C. M., Stein, J. L., Lian, J. B., van Wijnen, A. J., and Stein, G. S. (2011) A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. Proc. Natl. Acad. Sci. U.S.A. 108, 9863-9868
35. Corney, D. C., Flesken-Nikitin, A., Godwin, A. K., Wang, W., and Nikitin, A. Y. (2007) MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 67, 8433- 8438
36. He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., Jackson, A. L., Linsley, P. S., Chen, C., Lowe, S. W., Cleary, M. A., and Hannon, G. J. (2007) A microRNA component of the p53 tumour suppressor network. Nature 447, 1130-1134
37. Eliseev, R. A., Dong, Y. F., Sampson, E., Zuscik, M. J., Schwarz, E. M., O'Keefe, R. J., Rosier, R. N., and Drissi M. H. (2008) Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apo-ptosis. Oncogene 27, 3605-3614
38. van der Deen, M., Akech, J., Lapointe, D., Gupta, S., Young, D. W., Mon-tecino, M. A., Galindo, M., Lian, J. B., Stein, J. L., Stein, G. S., and van Wijnen, A. J. (2012) Genomic promoter occupancy of runt-related transcription factor RUNX2 in Osteosarcoma cells identifies genes involved in cell adhesion and motility. J.Biol. Chem. 287, 4503-4517
39. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y.-H., Inada, M., Sato, M., Okamoto, R., Kitamura, Y., Yoshiki, S., and Kishimoto, T. (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89, 755-764
40. Liu, J. C., Lengner, C. J., Gaur, T., Lou, Y., Hussain, S., Jones, M. D., Bo-rodic, B., Colby, J. L., Steinman, H. A., van Wijnen, A. J., Stein, J. L., Jones, S. N., Stein, G. S., and Lian, J. B. (2011) Runx2 protein expression utilizes the Runx2 P1 promoter to establish osteoprogenitor cell number for normal bone formation. J.Biol. Chem. 286, 30057-30070
41. Lou, Y., Javed, A., Hussain, S., Colby, J., Frederick, D., Pratap, J., Xie, R., Gaur, T., van Wijnen, A. J., Jones, S. N., Stein, G. S., Lian, J. B., and Stein, J. L. (2009) A Runx2 threshold for the cleidocranial dysplasia phenotype. Hum. Mol. Genet. 18, 556-568
42. Yoshida, C. A., Furuichi, T., Fujita, T., Fukuyama, R., Kanatani, N., Ko-bayashi, S., Satake, M., Takada, K., and Komori, T. (2002) Core-binding factor β interacts with Runx2 and is required for skeletal development. Nat. Genet. 32, 633-638
43. Yoshida, C. A., Yamamoto, H., Fujita, T., Furuichi, T., Ito, K., Inoue, K., Yamana, K., Zanma, A., Takada, K., Ito, Y., and Komori, T. (2004) Runx2 and Runx3 are essential for chondrocyte maturation, and Runx2 regulates limb growth through induction of Indian hedgehog. Genes Dev. 18, 952-963
44. Kansara, M., Tsang, M., Kodjabachian, L., Sims, N. A., Trivett, M. K., Ehrich, M., Dobrovic, A., Slavin, J., Choong, P. F., Simmons, P. J., Dawid, I. B., and Thomas, D. M. (2009) Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates os-teosarcomagenesis in mice. J. Clin. Invest. 119, 837-851
45. Wei, J., Shi, Y., Zheng, L., Zhou, B., Inose, H., Wang, J., Guo, X. E., Gross-chedl, R., and Karsenty, G. (2012) miR-34s inhibit osteoblast proliferation and differentiation in the mouse by targeting SATB2. J. Cell Biol. 197, 509-521
46. Zaidi, S. K., Pande, S., Pratap, J., Gaur, T., Grigoriu, S., Ali, S. A., Stein, J. L., Lian, J. B., van Wijnen, A. J., and Stein, G. S. (2007) Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc. Natl. Acad. Sci. U.S.A. 104, 19861-19866